Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) Stock

About Guangzhou Wondfo Biotech Co.,Ltd

Guangzhou Wondfo Biotech Co.,Ltd operates as a biotechnology enterprise, specializing in the research, development, production, and distribution of point-of-care testing (POCT) products. The company additionally provides rapid diagnostic tools and comprehensive solutions for managing chronic diseases. Its product catalog features an array of rapid test kits, addressing conditions like COVID-19, substance abuse, certain cancers, infectious diseases, fertility, and sexually transmitted infections. Furthermore, Wondfo Biotech offers immunofluorescence devices designed to identify cardiovascular conditions, inflammatory markers, kidney damage, hormonal imbalances (including sex hormones and thyroid function), diabetes, and specific tumor indicators. The firm also supplies analytical instruments, such as blood gas, optical coagulation, and dry chemistry analyzers. Established in 1992, the company's main operations are based in Guangzhou, China.

Guangzhou Wondfo Biotech Co.,Ltd is led by CEO Zhongxiong Peng, employs 2,443 people, headquartered in Guangzhou, CN, publicly traded since 2015.

over the past 52 weeks the stock has ranged between $15.40 and $26.29, and currently trades 39.1% below its 52-week high.

Official website: www.wondfo.com

Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ) — frequently asked questions